Patient characteristics
| Baseline characteristic . | CLB (n = 24) . | CLB+R (n = 68) . | CLB+G (n = 69) . | Total (n = 161) . |
|---|---|---|---|---|
| Median time since diagnosis (median/range in months) | 50.4 | 31.9 | 30.6 | 35.6 |
| (0.5-269.2) | (0.2-215.2) | (0.2-269.0) | (0.2-269.2) | |
| Median age (range) (years) | 73 (48-85) | 74.5 (50-87) | 76 (62-89) | 75 (48-89) |
| >70, n (%) | 16 (66.7) | 52 (76.5) | 53 (76.8) | 121 (75.2) |
| >80, n (%) | 3 (12.5) | 8 (11.8) | 8 (11.6) | 19 (11.8) |
| Sex, n (%) | ||||
| Female | 11 (45.8) | 24 (35.3) | 21 (30.4) | 56 (34.8) |
| Male | 13 (54.2) | 44 (64.7) | 48 (69.6) | 105 (65.2) |
| Binet stage, n (%) | ||||
| A | 6 (25.0) | 17 (25.0) | 15 (21.7) | 38 (23.6) |
| B | 6 (25.0) | 20 (29.4) | 26 (37.7) | 52 (32.3 |
| C | 12 (50.0) | 31 (45.6) | 28 (40.6) | 71 (44.1) |
| Median total CIRS score (range) | 7 (0-18) | 8 (3-13) | 8 (1-18) | 8 (0-18) |
| Median WBC (range) (×103/µL) | 187.2 | 69.7 | 74.5 | 80.7 |
| (17.6-302.1) | (0.1-365.3) | (3.1-345.6) | (0.1-365.3) | |
| IGHV mutational status, N = 157, n (%) | ||||
| Unmutated | 15 (65.2) | 42 (62.7) | 40 (59.7) | 97 (61.8) |
| Mutated | 8 (34.8) | 25 (37.3) | 27 (40.3) | 60 (38.2) |
| CD38 expression, n (%) | ||||
| Negative (<30%) | 12 (50.0) | 34 (50.0) | 44 (63.8) | 90 (55.9) |
| Positive (≥30%) | 12 (50.0) | 34 (50.0) | 25 (36.2) | 71 (44.1) |
| ZAP-70 expression, n (%) | ||||
| Negative (<20%) | 9 (37.5) | 39 (57.4) | 43 (62.3) | 91 (56.5) |
| Positive (≥20%) | 15 (62.5) | 29 (42.6) | 26 (37.7) | 70 (43.5) |
| s-TK (U/L), N = 159, n (%) | ||||
| ≤10.0 | 10 (43.5) | 29 (42.6) | 31 (45.6) | 70 (44.0) |
| >10.0 | 13 (56.5) | 39 (57.4) | 37 (54.4) | 89 (56.0) |
| s-β2M (mg/L), N = 160, n (%) | ||||
| ≤3.5 | 12 (52.2) | 38 (55.9) | 43 (62.3) | 93 (58.1) |
| >3.5 | 11 (47.8) | 30 (44.1) | 26 (37.7) | 67 (41.9) |
| Hierarchical model by FISH, N = 154, n (%)* | ||||
| Del(17p) | 5 (20.8) | 0 (0.0) | 6 (9.1) | 11 (7.1) |
| Del(11q) | 3 (12.5) | 12 (18.8) | 8 (12.1) | 23 (14.9) |
| Tri(12) | 6 (25.0) | 17 (26.6) | 11 (16.7) | 34 (22.1) |
| Normal | 3 (12.5) | 13 (20.3) | 21 (31.8) | 37 (24.0) |
| Sole del(13q) | 7 (29.2) | 22 (34.4) | 20 (30.3) | 49 (31.8) |
| Conventional karyotyping, N = 154, n (%) | ||||
| Median number of aberrations (range) | 1 (0-7) | 1 (0-6) | 1 (0-8) | 1 (0-8) |
| 0 aberration | 6 (30.0) | 14 (21.2) | 28 (41.2) | 48 (31.2) |
| ≥1 aberration | 14 (70.0) | 52 (78.8) | 40 (58.8) | 106 (68.8) |
| ≥3 aberrations (complex aberrant) | 6 (30.0) | 9 (13.6) | 15 (22.1) | 30 (19.5) |
| Baseline characteristic . | CLB (n = 24) . | CLB+R (n = 68) . | CLB+G (n = 69) . | Total (n = 161) . |
|---|---|---|---|---|
| Median time since diagnosis (median/range in months) | 50.4 | 31.9 | 30.6 | 35.6 |
| (0.5-269.2) | (0.2-215.2) | (0.2-269.0) | (0.2-269.2) | |
| Median age (range) (years) | 73 (48-85) | 74.5 (50-87) | 76 (62-89) | 75 (48-89) |
| >70, n (%) | 16 (66.7) | 52 (76.5) | 53 (76.8) | 121 (75.2) |
| >80, n (%) | 3 (12.5) | 8 (11.8) | 8 (11.6) | 19 (11.8) |
| Sex, n (%) | ||||
| Female | 11 (45.8) | 24 (35.3) | 21 (30.4) | 56 (34.8) |
| Male | 13 (54.2) | 44 (64.7) | 48 (69.6) | 105 (65.2) |
| Binet stage, n (%) | ||||
| A | 6 (25.0) | 17 (25.0) | 15 (21.7) | 38 (23.6) |
| B | 6 (25.0) | 20 (29.4) | 26 (37.7) | 52 (32.3 |
| C | 12 (50.0) | 31 (45.6) | 28 (40.6) | 71 (44.1) |
| Median total CIRS score (range) | 7 (0-18) | 8 (3-13) | 8 (1-18) | 8 (0-18) |
| Median WBC (range) (×103/µL) | 187.2 | 69.7 | 74.5 | 80.7 |
| (17.6-302.1) | (0.1-365.3) | (3.1-345.6) | (0.1-365.3) | |
| IGHV mutational status, N = 157, n (%) | ||||
| Unmutated | 15 (65.2) | 42 (62.7) | 40 (59.7) | 97 (61.8) |
| Mutated | 8 (34.8) | 25 (37.3) | 27 (40.3) | 60 (38.2) |
| CD38 expression, n (%) | ||||
| Negative (<30%) | 12 (50.0) | 34 (50.0) | 44 (63.8) | 90 (55.9) |
| Positive (≥30%) | 12 (50.0) | 34 (50.0) | 25 (36.2) | 71 (44.1) |
| ZAP-70 expression, n (%) | ||||
| Negative (<20%) | 9 (37.5) | 39 (57.4) | 43 (62.3) | 91 (56.5) |
| Positive (≥20%) | 15 (62.5) | 29 (42.6) | 26 (37.7) | 70 (43.5) |
| s-TK (U/L), N = 159, n (%) | ||||
| ≤10.0 | 10 (43.5) | 29 (42.6) | 31 (45.6) | 70 (44.0) |
| >10.0 | 13 (56.5) | 39 (57.4) | 37 (54.4) | 89 (56.0) |
| s-β2M (mg/L), N = 160, n (%) | ||||
| ≤3.5 | 12 (52.2) | 38 (55.9) | 43 (62.3) | 93 (58.1) |
| >3.5 | 11 (47.8) | 30 (44.1) | 26 (37.7) | 67 (41.9) |
| Hierarchical model by FISH, N = 154, n (%)* | ||||
| Del(17p) | 5 (20.8) | 0 (0.0) | 6 (9.1) | 11 (7.1) |
| Del(11q) | 3 (12.5) | 12 (18.8) | 8 (12.1) | 23 (14.9) |
| Tri(12) | 6 (25.0) | 17 (26.6) | 11 (16.7) | 34 (22.1) |
| Normal | 3 (12.5) | 13 (20.3) | 21 (31.8) | 37 (24.0) |
| Sole del(13q) | 7 (29.2) | 22 (34.4) | 20 (30.3) | 49 (31.8) |
| Conventional karyotyping, N = 154, n (%) | ||||
| Median number of aberrations (range) | 1 (0-7) | 1 (0-6) | 1 (0-8) | 1 (0-8) |
| 0 aberration | 6 (30.0) | 14 (21.2) | 28 (41.2) | 48 (31.2) |
| ≥1 aberration | 14 (70.0) | 52 (78.8) | 40 (58.8) | 106 (68.8) |
| ≥3 aberrations (complex aberrant) | 6 (30.0) | 9 (13.6) | 15 (22.1) | 30 (19.5) |
According to Döhner et al.1